Keyword: EuroBiotech Report
The takeover gives Novo control of a platform that could support development of insulins that respond to glucose.
In this week's EuroBiotech Report, Pfizer, BioNTech ink $425 million deal, British biotechs reel in $247 million in VC cash and more.
In our EuroBiotech roundup this week, Crescendo hits a milestone in its Takeda pact, Adaptimmune dials up dosing and A1M Pharma shifts its focus.
Pfizer has also committed to up to $305 million in development, regulatory and commercial milestones to seal the deal.
The series C continues a transformative year defined by the acquisition of GSK's portfolio of approved and experimental rare disease gene therapies.
The series B round sees more big-name investors give cash to researchers whose earlier work on PARP inhibitor Lynparza put DDR on the map.
The takeover agreement comes one year after Vernalis was left reeling by a second FDA rejection in quick succession.
In this week's EuroBiotech Report, U.K. downplays risk of Brexit disruption, Boehringer inks gene therapy deal, Therachon raises $60 million and more.
In our EuroBiotech roundup this week, Bavarian Nordic posts RSV vaccine data, ADC starts a phase 2 trial and Silence shares a patent dispute update.
The Novo Holdings-led mezzanine round comes six months after Therachon began testing its FGFR3 ligand trap in healthy volunteers.